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Abstract 
Severe acute respiratory syndrome coronavirus two (SARS-CoV-2), the virus responsible for 
the coronavirus disease 2019 (COVID-19) pandemic, represents an unprecedented global 
health challenge. Consequently, a large amount of research into the disease pathogenesis 
and potential treatments has been carried out in a short time frame. However, developing 
novel drugs is a costly and lengthy process, and is unlikely to deliver a timely treatment for the 
pandemic. Drug repurposing, by contrast, provides an attractive alternative, as existing drugs 
have already undergone many of the regulatory requirements. In this work we used a 
combination of network algorithms and human curation to search integrated knowledge 
graphs, identifying drug repurposing opportunities for COVID-19. We demonstrate the value 
of this approach, reporting on eight potential repurposing opportunities identified, and discuss 
how this approach could be incorporated into future studies. 
Introduction 
Severe acute respiratory syndrome coronavirus two (SARS-CoV-2), the virus responsible for 
the coronavirus disease 2019 (COVID-19) pandemic, was discovered in Wuhan, China, in 
December 2019 1. SARS-CoV-2 is a member of the betacoronaviruses, a genus of enveloped 
positive-sense single-stranded RNA viruses. The symptom profile of COVID-19 infections 
vary, with a dry cough and fever most often reported 2 and resulting in a mild illness in most 
cases. However, severe illness has been reported as occurring in as many as 20% of 
laboratory-confirmed infections 3, depending on population demographics and country-specific 
testing protocols, with symptoms including acute myocardial injury 4 and acute kidney injury 5. 
Two other highly pathogenic coronaviruses are known 6: SARS-CoV-1, responsible for the 
SARS outbreak in 2002-2004, and the Middle East respiratory syndrome (MERS) coronavirus, 
responsible for the MERS outbreak in 2012.  Unlike SARS-CoV-1 and MERS-CoV, however, 
SARS-CoV-2 is widely reported to cause asymptomatic carriage 7 in some individuals, which 
has contributed to the rapid, global spread 8, and subsequent radical, world-wide restrictions 
on daily life to control transmission. The disease now represents an unprecedented global 
health challenge.  
Mechanism of infection 
Understanding of the mechanism of pathogenesis is a piecemeal process. One process that 
is particularly well understood is the entry of SARS-CoV-2 into human cells, which occurs via 
two major methods: TMPRSS2-dependent entry and TMPRSS2-independent entry 9. The first 
method relies on two human transmembrane proteins, ACE2 and TMPRSS2. The spike 
proteins of SARS-CoV-2, which mediate coronavirus entry to human cells, have been shown 
to have strong affinity for the human protein ACE2, which is highly expressed on the surface 
  
of different cell types, including lung epithelial cells and type II alveolar cells 10. Once the viral 
spike proteins have bound to ACE2, localised TMPRSS2 can activate the viral spike proteins 
and cleave the cytoplasm-facing domain of ACE2. This mechanism causes the virus’ 
membrane to fuse with the human cell’s membrane, allowing the viral genomic RNA to enter 
the cell, where it can replicate and facilitate the production of new virions. 
In the absence of localised TMPRSS2, SARS-CoV-2 can enter human cells expressing ACE2 
via another mechanism. In this process, the viral spike proteins bind to ACE2 and the ACE2 
receptor protein recruits clathrin, which initiates endocytosis of the virus. Usually, following 
endocytosis, proton pumps transport H+ ions into endosomes, lowering the internal pH, 
allowing the endosome to begin the process of becoming an endolysosome and breaking 
down anything within. However, the pH-dependent enzyme cathepsin L present in endosomes 
are used by SARS-CoV-2 to activate the viral spike proteins, which allow the virus to fuse with 
the endosomal membrane and release its genomic RNA into the host cell in preparation for 
replication and production of more virions. 
Repurposing drugs for the treatment of COVID-19 
Due to the rapid increase in COVID-19 cases, a large amount of research into the disease 
pathogenesis and potential treatment has been carried out in a short space of time. Given the 
rapid onset of the pandemic, there is an urgent need to identify new drugs that are able to 
treat the disease and improve patient outcomes 11,12. Developing novel drugs and taking them 
to market typically takes many years, so the traditional pathways are unlikely to provide a 
timely treatment for the current pandemic. The time pressures for new treatments make drug 
repurposing particularly attractive. Drugs approved for one indication (disease) may also 
happen to be efficacious for another.  If likely candidates for repurposing can be identified, the 
time to approval for a drug can be reduced to just a few months by drawing from the pool of 
the many thousands of drugs that have already been through the regulatory approval process, 
and are therefore well-characterised. Identifying high quality drug repurposing candidates is 
challenging. Many discoveries are serendipitous, for example from observations in clinics and 
trials 13. However, with the advent of network approaches to studying biology at a systems 
level, new computational approaches have emerged that allow a more systematic approach 
to drug repurposing 14–16. Networks are a convenient method to represent drugs, genes, 
proteins, diseases, etc., and the relationships between them. They support human 
investigation through visual exploration, while at the same time being amenable to 
computational analysis, enabling automated and systematic analysis.  
 
Drug repurposing algorithms derive new relationships between drugs, targets, diseases, 
genes etc., based on existing knowledge of these relationships 15, These new relationships 
can lead to hypotheses about novel repurposing opportunities and the evidence for them can 
be reviewed and then hypotheses tested in the laboratory and clinic. Computational drug 
repurposing prediction and human curation both require the availability of a variety of data 
sources that describe the molecular processes in a cell and their interaction with drugs. These 
data are typically distributed in a range of different data sources and databases and may be 
integrated after they have been represented as networks to form an integrated network or 
knowledge graph 17–19. Repurposing algorithms that operate over the data can vary from 
simple pattern matching or network module analysis, through to the application of artificial 
intelligence 20–24. The output of these algorithms are systematic computational predictions and 
  
therefore need human curation, with a range of expertise, to assess their value.  Therefore, 
the computational prediction of repurposable drugs is usually applied in an iterative fashion, 
coupled with the input of a human expert who is able to verify and generate hypotheses about 
new repurposing opportunities.  
 
The need for new drugs to treat COVID-19 has resulted in a large number of recent studies 
25–41. Antiviral drugs have been the most obvious target since some of these have been shown 
to be active against SARS. For example, drugs such as Elbasvir are under scrutiny to this 
effect 42. Other antiviral drugs, such as Remdesivir, originally employed for the treatment of 
Ebola, have recently been approved for the treatment of COVID-19 43. However, there is still 
a pressing need for more candidate drugs, especially those addressing the abnormal immune 
response seen in some patients 43,44. The wider search for repurposable drugs remains a field 
under active development.  Most of these studies are computational in nature and have 
resulted in many potential new drug candidates. These studies have employed a variety of 
strategies including network based analyses. Some of these candidates are now undergoing 
clinical trials to test their effectiveness 34.   
 
In this work we used a combination of network algorithms and human curation to search 
integrated knowledge graphs for drug repurposing opportunities for COVID-19. We aimed to 
highlight potential repurposing opportunities that are possibly novel in comparison to those 
published so far. We also introduce some newer features to our analytical process in an effort 
to improve accuracy by incorporating measures, which take data quality into account, and to 
speed up data verification by facilitating multiple curation.  
 
Many studies, for example that of Kumar 2020 41, have employed protein interaction networks 
to study the relationships between COVID-19 proteins, the proteins they interact with, and the 
molecular interaction networks in the cell. However, data quality is an important factor in the 
assignment of protein interactions, and has received little attention in studies to-date. Instead 
of using a standard protein interaction graph, we developed a probabilistic functional 
interaction network for human proteins that uses highly curated interactions from BioGrid as a 
gold standard to produce a weighted protein interaction network, where the weight indicates 
the confidence of a functional interaction. We then mapped onto this human probabilistic 
function integrated network (PFIN) the interactions with COVID-19 proteins, discovered 
experimentally in Gordon et al., 2020 27. 
  
The process of curating computational predictions, or manually analysing networks for new 
opportunities is a large-scale, time consuming task. The division of labour through network 
partitioning and crowdsourcing are promising approaches to more rapid verification of results 
45,46. However, one of the challenges facing this approach is the assignment of appropriate 
sections of a complex network to each curator. Since we were working with PFINs that 
included weighted edges, we were able to employ a clustering algorithm to partition the 
probabilistic network into functionally related subgraphs. Those subgraphs containing COVID-
19 protein interactors were then enriched with information from previously integrated networks 
to add relationships to drugs, diseases, genes, pathways and so on. Each subgraph then 
represents a unit of the network that was systematically assigned to a curator for analysis. In 
this fashion, a large scale task is broken down and becomes faster with more curators 
participating in the exercise. Here we present details of our approach to the development and 
  




This work extends approaches developed by Mullen et al. 47. In brief, a semantic knowledge 
graph was constructed in Neo4j, comprising data about existing, approved drugs. The data 
sources contributing to the knowledge graph are shown in Table 1. 
 
Data source Date obtained Nodes 
contributed 
Edges contributed 
UniProt 48 2020-02-11 Proteins Gene -[encodes]- Protein 




2020-02-11 Disorders Disorder -[is subset of]- 
Disorder  
Drug Central 51 2018-08-26  Drug -[has target]- Protein 
Drug -[has indication]- 
Disorder 
OMIM 52 2020-02-07  Gene -[associated with]- 
Disorder 
DisGeNET 53 2019-12-02  Gene -[associated with]- 
Disorder 
NCBI Gene Info 54 2020-02-11 Genes  
Table 1: Databases integrated as part of this study.  
 
Using the Neo4j knowledge graph, two approaches were taken to identifying drug repurposing 
candidates. In the first approach, a search of literature on COVID-19 and SARS-CoV-2 was 
carried out to identify current knowledge on mechanisms of disorder pathogenesis, including 
genes and proteins in Homo sapiens and SARS-CoV-2 that are involved in this process. 
Based on the results of the literature search, semantic queries were devised to explore the 
local neighbourhood around identified concepts of interest in the knowledge graph. 
 
In the second approach, a PFIN was created from BioGrid 55 v181. A PFIN is a network in 
which the nodes (in this case, genes) are linked via weighted edges, with the weight 
representing the confidence that the two genes functionally interact. The PFIN was 
constructed using a method devised by Lee et al. 56. In brief, BioGrid v181 was partitioned into 
high-throughput (HTP) datasets and low-throughput (LTP) datasets, with low-throughput 
datasets being defined as datasets containing fewer than 100 interactions. By considering the 
LTP datasets as a gold-standard, log likelihood scores (LLS) for the high-throughput datasets 
were calculated using an approach as described by Lee et al. 56,  
 
  
𝐿𝐿𝑆	 = 	𝑙𝑛 '𝑃(𝐿|𝐸)	/	∼ 𝑃(𝐿|𝐸)𝑃(𝐿)	/	∼ 𝑃(𝐿) / 
 
where, P(L|E) and ~P(L|E) represent the  frequencies of linkages (L) observed in dataset (E) 
between genes in the gold-standard, and absent from the gold-standard, respectively, and, 
P(L) and ~P(L) represent the prior expectation of linkages between genes in the gold-standard, 
and absent from the gold-standard, respectively. 
 
Datasets with a LLS of 0 or lower were discarded, and the remaining datasets were sorted in 
order of LLS, and integrated using the following formula: 
 𝑊𝑆	 = 	123	4	5 𝐿31.1 3	8	5  
 
where,  L1  is  the  highest  LLS  score  and  Ln that  with  the  lowest  of  a  set  of  n datasets. 
The denominator selected to give more weight to datasets with higher confidence was 1.1, as 
used in previous work by James et al. 57. 
 
The PFIN was clustered using a weighted MCL algorithm with the default parameters and 
viewed in Cytoscape 58,59. Next, for the set of Homo sapiens proteins identified as interacting 
with SARS-CoV-2 proteins by Gordon et al.60, clusters from the PFIN containing genes that 
encode at least one of these proteins were extracted, decorated with edges and nodes from 
the knowledge base (Figure 1), and returned.  
 
UNWIND {gene_identifiers} as i 
MATCH (gene:Gene {primaryDomainId:i}) 
OPTIONAL MATCH (gene)<-[peg:ProteinEncodedBy]-(pro:Protein) 
OPTIONAL MATCH (pro)<-[dht:DrugHasTarget]-(drug) 
OPTIONAL MATCH (drug)-[dsim:MoleculeSimilarityMolecule]-(drug1) 
WHERE dsim.morganR2 > 0.5 
OPTIONAL MATCH (gene)-[gawd:GeneAssociatedWithDisorder]-(disorder) 
RETURN gene, peg, pro, drug, disorder, dht, gawd, dsim, drug1 
Figure 1: Cypher query used to decorate genes in PFIN clusters that have at least one gene encoding a protein that interacts 
with a SARS-CoV-2 protein. Information obtained from the knowledge base includes (1) proteins encoded by the genes, (2) drugs 
that target any proteins in (1), (3) drugs with similarity drugs in (2), (4) disorders associated with the genes in the PFIN cluster. 
 
Due to limitations of the integrated database we constructed, such as a lack of side-effect data 
and missing annotations for drug actions on their targets, clusters required manual curation to 
identify promising targets. Thus, this analysis was crowdsourced amongst various 
contributors. A Trello system was used to coordinate the distribution of clusters, collate 





Results from the cluster analysis from multiple curators were assimilated and integrated and 
are presented on a per-drug (or per-drug class, where appropriate) basis. Each section below 
describes (1) the drug / class, (2) the method(s) used to identify the drug / class as a candidate, 
and (3) an explanation of any relevant literature to support or refute the drug candidacy.   
Theophylline 
Theophylline (IUPAC name: 1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione) is a 
methylxanthine drug with activities including smooth muscle relaxation and bronchial dilation. 
Indicated for conditions such as chronic obstructive pulmonary disorder (COPD) and asthma, 
theophylline exerts its activity through competitive inhibition of type III and IV 
phosphodiesterase 61. Clustering of the PFIN revealed a cluster of genes, one of which, 
DNAJC11, encodes the DNA J homolog subfamily C member 11 protein (Q9NVH1), which 
Gordon et al. 27 reported as interacting with the SARS-CoV-2 E protein. SARS-Cov2 E 
encodes the envelope protein, E, which plays a role in the structure and maturation of the virus 
62. DNAJC11 is a mitochondrial protein which is required for mitochondrial inner membrane 
organization which associates with the mitochondrial contact site and cristae organizing 
system (MICOS) complex 62,63. The PFIN suggests that DNAJC11 has a high likelihood of 
being functionally related to RIC3, which encodes the protein RIC3 (Q7Z5B4) -- a protein 
target of theophylline 64. RIC3 promotes functional expression of homomeric alpha-7 and 
alpha-8 nicotinic acetylcholine receptors at the cell surface and is found in endoplasmic 
reticulum and the golgi apparatus 65. The relevance of the functional relationship between 
DNAJC11 and RIC3 is unclear, however the interaction was identified by Affinity Capture-
Mass Spectroscopy, which implies a physical binding. It is possible, therefore, that RIC3 
complexes with DNAJC11 (although current evidence has them expressed in different 
organelles) and theophylline could block the binding of DNAJC11 by SARS-CoV-2 E. 
Interestingly, DNAJC11 has well-conserved orthologues in other species, such as mouse, rat, 




Figure 2: Network showing decorated PFIN cluster containing gene encoding a protein targeted by Theophylline. The inset shows 
a larger view of part of a connected component including Theophylline. In this, the red node is Q9NVH1, the pink nodes are 
genes, and the blue node is Theophylline. Q9NVH1 is a high-confidence interactor of the SARS-CoV-2 nsp4 protein. 
 
Calmodulin inhibitors 
Calmodulin is a ubiquitous calcium binding protein which binds to transmembrane proteins 
such as ACE 67. As described in the introduction, ACE transmembrane proteins have a distinct 
role in Covid-19 infection 9. Calmodulin plays a crucial role in regulating ACE2 presence on 
the cell surface by binding to the cytoplasmic tail of ACE2 68. A potential target for decreasing 
infection and viral loading could, therefore, be the use of calmodulin inhibitors, acting to 
decrease the association of the two proteins. Without the binding of calmodulin to ACE2, the 
cells start to shed the ectodomain of ACE2, leading to decreased expression and catalytic 
activity 67. Querying our knowledge graph for approved drugs that inhibit CALM1 (P0DP23), 
we identified 10 existing, approved drugs that are labelled as inhibitors of calmodulin, indicated 
for a range of conditions including hypertension, seasonal allergies, and antidepressants (full 
list in Appendix 1A). 
Angiotensin II 
Angiotensinogen is a small peptide hormone which, as part of the renin-angiotensin-
aldosterone system (RAAS), is involved in the regulation of blood pressure 69. Via the action 
of renin, angiotensinogen is converted into angiotensin I. In turn, angiotensin I, via the action 
of angiotensin converting enzyme (ACE), is converted into angiotensin II. Critically, ACE2 
converts angiotensin II into angiotensin (1-7), an effector of nitric oxide-dependent vasodilation 
which has been implicated in attenuating acute lung injury 70. The role of drugs which inhibit 
the RAAS, such as commonly prescribed antihypertensive agents (e.g., ACE inhibitors and 
  
angiotensin receptor blockers) is controversial, with arguments proposed for both harmful and 
protective effects 71–73. Given that angiotensin II is, itself, an approved drug, it may have a 
therapeutic use in COVID-19 via the actions of angiotensin (1-7). Angiotensin II has already 
been suggested as a possible therapeutic agent, and is currently being investigated 
(NCT04332666). 
Cathepsin L and TMPRSS2 synergistic targets 
Whilst inhibition of the ACE2 receptor may seem an ideal target for treating COVID-19, as it 
is required for both major mechanisms of viral entry into host cells, it has been shown that 
ACE2 is essential for repairing damage to lung tissues. Instead, it may be possible to inhibit 
TMPRSS2, which could lead to most virus particles entering the host cell via endosomes. If 
cathepsin L is also inhibited, the endosome-enclosed viruses will be unable to escape, 
allowing the endosomes to progress fully to endolysosomes and destroy the virus particles. In 
this way, it may be possible to not only prevent entry into the host cell and subsequent 
replication, but also reduce overall viral load by enabling the body to destroy SARS-CoV-2. 
Drug name Description Drug groups 
(according to 
DrugBank) 
Telaprevir Antiviral medication used as part of 
combination therapy in hepatitis C infection 
Approved, withdrawn 
Boceprevir Antiviral medication used as part of 








Felbinac  Experimental 
Fostamatinib Indicated for treatment of rheumatoid arthritis 






Table 2: Cathepsin L inhibitors identified in our database. A search of https://clinicaltrials.gov and https://covid-trials.org found 
no trials related to COVID-19 for the drugs listed. 
Previous studies have suggested that an already approved drug, camostat mesylate, could be 
used as a TMPRSS2 inhibitor 74. In this study, through rational querying of the knowledge 
graph, drug candidates for putative cathepsin L inhibitors have been identified (Table 2). 
These candidates are all approved drugs. Two of these drugs, telaprevir and boceprevir, have 
been used previously to help treat chronic hepatitis C infections; however, both have since 
been discontinued due to common side effects such as severe rashes, anemia, decreased 
neutrophils, and fatigue. Sodium aurothiomalate is a gold-containing compound approved for 
use treating rheumatoid arthritis. This drug is not currently commonly sold due to a difficulty in 
sourcing sodium aurothiomalate. The final potential cathepsin L inhibitor identified in this study 
is fostamatinib, which is approved for use against chronic immune thrombocytopenia. Other 
drug repurposing studies for COVID-19 have also identified this drug as a potential candidate, 
  
but as an ACE2 inhibitor 75. These same studies, however, did not evaluate it as a cathepsin 
L inhibitor. Based on this and previous studies, it is therefore possible that a combined therapy 
of camostat mesylate and fostamatinib may aid in treating COVID-19. 
Interestingly, fostamatinib was separately identified as a drug candidate via the PFIN 
clustering approach (Figure 3). Fostamatinib has serine/threonine-protein kinase TBK1 
(Q9UHD2) as a drug target, which was also identified by Gordon et al. 27 as being a protein 
that interacts with a SARS-CoV-2 protein. However, the relevance of this interaction, if any, is 
unclear to us. 
 
Figure 3: Network view of a cluster of the PFIN in which fostamatinib (highlighted in yellow) is identified as targeting a Homo 
sapiens protein, Q9UHD2 (red). Q9UHD2 is a high-confidence interactor of the SARS-CoV2 nsp13 protein. 
Potential antiviral modulators of inflammation 
Severe COVID-19 disease often includes an exaggerated inflammatory response. Stebbing  
et al. suggested that combining antiviral and anti-inflammatory treatments is a possible means 
of reducing disease severity 76. In their study, they examined the affinity between antiviral 
drugs (in particular, through inhibition of numb-associated kinases (NAKs)) and drug targets 
that may be useful in attenuating inflammation (e.g. through inhibition of Janus Kinases 
(JAKs)). As a result of the study, Stebbing et al. identified and discussed a range of drugs, 
including baricitinib, tofacitinib, and ruxolitinib.  
 
To determine whether there were any additional drug candidates not discussed by Stebbing 
et al. 76, we queried our dataset for drugs targeting the NAKs and JAKs identified in the paper. 
These proteins were as follows: AAK1 (Q2M2I8), BIKE (Q9NSY1), GAK (O14976), JAK1 
(P23458), JAK2 (O60674), JAK3 (P52333), and TYK2 (P29597). In addition to baricitinib, 
tofacitinib, and ruxolitinib, we also identified fostamatinib as a potential drug candidate. In fact, 
  
in our knowledge graph, fostamatinib was the only drug recorded as having all the 
aforementioned proteins as drug targets.  
 
Epidermal growth factor receptor (EGFR) inhibitors 
EGFR (P00533) is a protein implicated in tissue fibrosis, due to its role in TGF-β1 dependent 
fibroblast-myofibroblast differentiation. Venkataraman and Frieman, 2017 77, suggested that 
inhibiting EGFR signalling prevents excessive fibrotic responses and, thus, lung damage, 




WHERE ("approved" in drug.drugGroups) AND ("inhibitor" in 
dt.actions OR "suppressor" in dt.actions)  
RETURN drug, n 
Figure 4: Neo4j query used to identify EGFR inhibitors. 
 
Running the query in Figure 4 identified eight approved drugs that were EGFR inhibitors -- 
brigatinib, afatinib, osimertinib, fostamatinib, dacomitinib, neratinib, vandetanib, and 
panitumumab.  
 
Lobeline, Nicotine and Galantamine 
Two COVID proteins - ORF9c and NSP4 - have interactions with mitochondria-related human 
proteins ZNT6 (Q6NXT4, encoded by the SLC30A6 gene, transmembrane zinc transporter 
located in the golgi apparatus) and TIM29 (Q9BSF4, encoded by the TIMM29 gene, inner 
mitochondrial membrane translocase), respectively 27. The genes encoding these proteins 
were both identified as having a high-confidence functional interaction with the neuronal 
acetylcholine receptor subunit alpha-9 (NACHR9) protein (Q9UGM1, gene name CHRNA9) 
78,79. These relationships are shown in Figure 5. NACHR9 is a is part of the ligand-gated ionic 
channel and nicotinic acetylcholine receptor superfamilies, and forms homo- or hetero-
oligomeric divalent cation channels in the plasma membrane 80. 
  
  
Figure 5: Portion of one of the PFIN clusters, showing the local neighbourhood around the human protein NACHR9. Lobeline can 
be seen to target the protein encoded by CHRNA9. The two human proteins (Q6NXT4 and Q9BSF4) shown to interact with 
SARS-CoV-2 proteins are highlighted in red. Q6NXT4 is a high-confidence interactor of the SARS-CoV-2 orf9c and Q9BSF4 is 
a high-confidence interactor of the SARS-COV-2 nsp4. 
 
According to DrugBank, NACHR9 is targeted by the following small molecules: lobeline; 
galantamine; nicotine; tetraethylammonium; RPI-78M and, ATG003. Lobeline, in its natural 
form from the Lobelia plant, has been proposed and applied for therapeutic uses including 
respiratory disorders (such as asthma) as a stimulant to treat wheezing, uncontrollable 
coughing and chest tightness 81, and has been reported to improve acute lung injury in cell 
lines 82. There have been promising studies carried out on mice where lobeline helped to treat 
acute lung injury 83, but human studies are still required. Nicotine induces ACE2 
overexpression in Human Bronchial Epithelial Cells (HBEpC) via alpha7-nicotinic receptor (ɑ7-
nAChR)84, a paralog of NACHR9. Galantamine is a reversible, competitive inhibitor of 
acetylcholinesterase (AChE), which catalyses the breakdown of ACE, and is an allosteric 
modulator of nAChRs. It is currently approved for mild to moderate dementia and Alzheimer’s.  
 
Quercetin 
Quercetin is a polyphenol flavonoid found in many plants 85 and has been reported as having 
anti-inflammatory and anti-viral properties 86,87. In one of the PFIN clusters (relevant subset 
shown in Figure 6), quercetin was identified as targeting the human protein casein kinase II 
subunit beta (CK2-beta) protein (P67870, localised throughout the cell), which Gordon et al. 
reported as being a high-confidence interactor of the SARS-CoV-2 N protein 27. Two CK2-beta 
molecules, together with a single alpha and alpha’ subunit together form the tetramer casein 
kinases II (CK2). CK2 acts as a serine/threonine-selective protein kinase, involved in cell cycle 
regulation, and is implicated in disorders of cell proliferation (e.g. tumours) 88.  Interestingly, 
CK2 has been found to be stimulated in other viral infections 89, and has various roles in the 
infection cycles of different viruses 90,91. Further, Gordon et al. suggested CK2 inhibition as a 
possible therapeutic approach for COVID-19 60, as CK2 downregulates stress granule 
formation 92 which is associated with enhanced viral replication in other coronavirus infections 
  
93. Thus, depending on the nature of the interaction between quercetin and CK2, it may be of 
benefit. 
 
Quercetin has already been suggested as a possible therapeutic to mitigate the severity of 
SARS-CoV-2 infection, as quercetin alters the expression of 30% of the human proteins that 
are targets of SARS-CoV-2 proteins 94.  
 
  
Figure 6: Portion of one of the PFIN clusters, showing casein kinase II subunit beta (P67870) (red, lower right) as a drug target 
of quercetin. P67870 is a high-confidence interactor of the SARS-CoV-2 N protein. 
Discussion 
In summary, this study aimed to build on existing studies that have used knowledge 
frameworks to generate hypotheses about drug repurposing opportunities for COVID-19. As 
in other studies, an integrated dataset was developed, extending a drug repurposing 
framework developed by Mullen et al. 47. We aimed to enhance the knowledge network 
approach through the use of PFINs to act as a framework to guide the hypothesis generation 
process. The use of PFINs allowed us to scale the data curation process in a systematic 
fashion, exploiting the combined effort of multiple curators. Our approach could act as a 
template for future studies, with richer knowledge graphs, the incorporation of algorithmic 
predictions for drug repurposing and a much larger set of curators. The drugs we identified for 
repurposing are illustrative of the value of our approach. Due to the rapidly developing nature 
of studies on SARS-CoV-2 and COVID-19, it is difficult to identify which candidates are truly 
novel, however, even in instances where candidates have already been suggested by other 
studies, our approach can still provide additional supporting (or refuting) evidence.  
 
  
The results presented in this study are grouped by drug class. Where possible, we have tried 
to avoid suggesting specific instances of drugs (and focused on classes instead), in part 
because we recognise that our database is not complete. Further, ethically, there may be 
socioeconomic reasons for selecting one member of a drug class over another, such as supply 
and demand or the dependence of a subpopulation on a given drug. However, there are some 
noteworthy cases where focusing on specific drugs within a class is necessary. For example, 
fostamatinib has emerged as a drug candidate in a number of different contexts as an anti-
inflammatory agent, as an EGFR inhibitor, and as a cathepsin L inhibitor, establishing it as a 
promising candidate.  
 
One limitation of in silico drug repurposing studies is that, depending on the algorithms 
employed, many drug repurposing candidates can be suggested. Refinement of a large set of 
drug candidates often requires many person-hours of time to curate, particularly when 
including time taken to understand the mechanisms / pathways involved. By (1) leveraging a 
PFIN-based clustering approach and (2) focusing on clusters containing high-confidence 
interactors with SARS-CoV-2 proteins, we were able to reduce the drug candidate search 
space significantly. Using a crowd-sourcing approach to analyse the clusters allowed 
individuals to curate sets of drug candidates that were likely to be mechanistically related, 
providing a logical partitioning of work. Curation allowed us to focus on drugs with additional 
context (e.g., pharmacological, biological) evidence to support or refute the drugs discussed, 
thus providing a balanced perspective on the drugs discussed. In future studies, it might be 
interesting to research systematic and computational approaches to integrating and ranking 
the findings of curators, perhaps building on larger systems for data sharing and integration 
such as FAIRDOMHub 95.  
 
There are a number of caveats to this research which need to be addressed to ensure results 
are taken in an appropriate context. Firstly, the data sources contributing to our integrated 
semantic network are limited in scope and could be expanded. For example, the graph 
includes connections between drugs and their protein targets, but the nature (e.g. “inhibitory”, 
“stimulatory”, “suppressor”) is not always recorded. Secondly, computational prediction can 
only ever generate suggestions or hypotheses based on the analysis of the limited data 
available. Thus, for any drug repurposing candidates suggested, it is critical that these are 
manually curated by experts in medicine, pharmacology, and human biology. Due to recent 
concerns over the potential for harm in COVID-19 preprints, we want to stress that this 
research should not be used to inform clinical practice, nor should people change their 
behaviour on the basis of it 96. 
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1A: List of Calmodulin Inhibitors found in dataset: 
 
 
Drug Indication (if recorded in database) 
Phenoxybenzamine  
Chlorpromazine Psychotic disorder, acute intermittent 
porphyria, schizophrenia, manic bipolar 
affective disorder 
Nifedipine Hypertensive disorder, prinzmetal angina 
Pimozide Tourette syndrome 
Promethazine Atopic conjunctivitis, urticaria, vasomotor 
rhinitis, seasonal allergic rhinitis 




Fluphenazine Schizophrenia, psychotic disorder 
Cinchocaine  
  
 
